The recent outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2),
previously known by the provisional name 2019 novel coronavirus (2019‐nCoV), in the
city of Wuhan in China's Hubei province in 2019–2020 has been causing significant
numbers of mortality and morbility in humans with the coronavirus infection diseases
(COVID‐19) with fever, severe respiratory illness, and pneumonia.[
1
,
2
,
3
] Till April 8, 2020, there have been over 1 431 973 confirmed cases globally, leading
to at least 82 085 deaths. These SARS‐CoV‐2 isolates belong to the Betacoronavirus
genus of the Coronaviradae family which is an enveloped single‐stranded RNA virus
containing a 30 kb genome with 14 open reading frames including four major viral structure
proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins.[
4
,
5
,
6
,
7
] The S gene sequences of SARS‐CoV‐2 isolates have a 93.1% nucleotide sequence identity
to the Rhinolophus affinis bat coronavirus RaTG13, but only less than 75% nucleotide
sequence identity to the severe acute respiratory syndrome coronavirus (SARS‐CoV).
The viral S sequences of SARS‐CoV‐2 compared to SARS‐CoV have three additional short
insertions in the N‐terminal domain, and four out of five key residues changes in
the receptor‐binding motif of S protein receptor binding domain (RBD).[
6
,
7
] Although both SARS‐CoV‐2 and SARS‐CoV share the same human cellular receptor‐angiotensin
converting enzyme II, SARS‐CoV‐2 appears to be more readily transmitted from human
to human.[
1
,
8
,
9
]
The S protein is the major target for COVID‐19 vaccine development, mainly based on
the elicitation of virus neutralizing antibodies as the immune correlates to vaccine
protection. The current status of COVID‐19 vaccine development includes, i) three
phase I vaccine candidates, ii) 11 preclinical vaccine candidates, and iii) 26 research‐stage
vaccine candidates (Table 1; [https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker?feed=Regulatory-Focus?utm_source=Facebook&utm_medium=social&utm_campaign=Regulatory-Focus]).
Most of these vaccine candidates are based on the S antigen either as inactivated
vaccines, subunit vaccines, viral vectored vaccines, and nucleic acid‐based DNA or
mRNA vaccines. Among these vaccine candidates, the Coalition for Epidemic Preparedness
Innovations (CEPI) has provided funding to develop COVID‐19 vaccines using the following
platform technology: a) Curevac Inc. (mRNA), b) Inovio Pharmaceuticals Inc. (DNA),
c) Moderna, Inc. (mRNA), d) University of Queensland (molecular clam), e) Novavax
(nanoparticles), f) University of Oxford (adenovirus vector), g) University of Hong
Kong (live‐attenuated influenza virus), and h) Institute of Pasteur (measles vector)
to accelerate the development of vaccines and enable equitable access to these vaccines
for people during outbreaks [https://cepi.net/covid-19/].
Table 1
The current status of COVID‐19 vaccine development
Company
Vaccine candidates
Status
Moderna
mRNA‐1273
Phase I
NCT04283461
CanSino Biologics
Ad5‐nCoV
Phase I
ChiCTR2000030906
Inovio
INO‐4800 (DNA)
Phase I
NCT04336410
Pfizer and BioNTech
BNT162 (mRNA)
Pre‐clinical
Novavax
Recombinant nanoparticle vaccine
Pre‐clinical
CureVac
mRNA‐based vaccine
Pre‐clinical
Generex
Ii‐Key peptide vaccine
Pre‐clinical
Vaxart
Oral recombinant vaccine
Pre‐clinical
Imperial College London
Self‐amplifying RNA vaccine
Pre‐clinical
Medicago
Plant‐based vaccine (VLP)
Pre‐clinical
Takis Biotech
DNA‐based vaccine
Pre‐clinical
J&J and BARDA
AdVac and PER.C6 systems
Pre‐clinical
Altimmune
Intranasal vaccine
Pre‐clinical
University of Saskatchewan
Not revealed
Pre‐clinical
Clover and GSK
S‐Trimer
Research
Heat Biologics
gp96‐based vaccine
Research
CSL and University of Queensland
Molecular clamp vaccine
Research
Sanofi
Not revealed
Research
iBio
Plant‐based vaccine
Research
ExpreS2ion Biotechnologies
Not revealed
Research
EpiVax
Ii‐Key peptide vaccine
Research
Codagenix
Live attenuated vaccine
Research
Zydus Cadila
DNA and/or live attenuated recombinant vaccine candidate
Research
Sinovac
Formalin‐inactivated and alum‐adjuvanted candidate vaccine
Research
Geovax and Bravovax
Modified Vaccinia Ankara virus like particles (MVA‐VLP) vaccine
Research
University of Oxford
Chimpanzee adenovirus vaccine vector (ChAdOx1)
Research
Greffex
Adenovirus‐based vector vaccine
Research
Walter Reed and USAMARIID
Not revealed
Research
MIGAL
Modified avian coronavirus vaccine
Research
Vaxil Bio
Protein subunit COVID‐19 vaccine candidate
Research
AJVaccines
Not revealed
Research
Baylor
Re‐purposed SARS vaccine;
S1 or RBD protein vaccine
Research
Institut Pasteur
Not revealed
Research
Tonix Pharmaceuticals and Southern Research
Horsepox vaccine with percutaneous administration
Research
Fudan University, Shanghai Jiao Tong University, and RNACure Biopharma
mRNA‐based vaccine
Research
Arcturus Therapeutics and Duke‐NUS
Self‐replicating RNA and nanoparticle non‐viral delivery system
Research
University of Pittsburgh
Not revealed
Research
ImmunoPrecise
Not revealed
Research
Peter Doherty Institute for Infection and Immunity
Not revealed
Research
Tulane University
Not revealed
Research
John Wiley & Sons, Ltd.
This article is being made freely available through PubMed Central as part of the
COVID-19 public health emergency response. It can be used for unrestricted research
re-use and analysis in any form or by any means with acknowledgement of the original
source, for the duration of the public health emergency.
To date, many previous studies of SARS‐CoV, Middle East respiratory syndrome‐related
coronavirus (MERS‐CoV), and other coronavirus vaccines revealed several safety concerns
associated with the use of coronavirus S‐based vaccines, including inflammatory and
immunopathological effects such as pulmonary eosinophilic infiltration and antibody‐dependent
disease enhancement (ADE) following subsequent viral challenge of vaccinated animals.[
10
,
11
,
12
,
13
,
14
,
15
,
16
,
17
,
18
,
19
,
20
,
21
] The anti‐S antibodies for ADE may facilitate uptake by macrophage expressing FcR,
leading to macrophage stimulation and the production of proinflammatory cytokines
(IL‐6, IL‐8, and MCP1) and loss of tissue‐repaired cytokine (TGFβ).[
22
] Moreover, the Th2‐associated immunopathology has been documented for the inactivated
vaccines of respiratory syncytial virus after viral challenge[
23
,
24
,
25
] and the inactivated vaccines of MERS‐CoV after virus challenge.[
20
] Thus, the safety and the potentially harmful responses in vaccines to develop ADE
antibodies against any coronaviruses should be carefully assessed in human trials.[
26
] It has been proposed that the neutralizing epitope‐rich S1 region, or the RBD region,
instead of the entire full‐length S protein as an alternative target for MERS‐CoV
vaccine development.[
27
] Whether the use of S1 or RBD antigen of SARS‐CoV‐2, or the selection of Th1‐skewed
adjuvants rather than alum adjuvant, can avoid the inflammatory, immunopathological,
and ADE effects, requires further studies from animal models and human trials. These
findings are particularly important for developing a safe and effective COVID‐19 vaccine.
Suh‐Chin Wu
Conflict of Interest
The author declares no conflict of interest.